- Home
- IOT vs MRNA Comparison
IOT vs MRNA Comparison
Compare IOT & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IOT | MRNA |
|---|---|---|
| Founded | 2015 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.3B | 26.7B |
| IPO Year | 2021 | 2018 |
Fundamental Metrics
Financial Performance| Metric | IOT | MRNA |
|---|---|---|
| Price | $40.97 | $142.04 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 12 | 12 |
| Target Price | ★ $45.42 | $34.27 |
| AVG Volume (30 Days) | 4.6M | ★ 27.1M |
| Earning Date | 06-04-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 92.86 | 21.77 |
| EPS | ★ 0.08 | N/A |
| Revenue | $1,618,635,000.00 | ★ $19,263,000,000.00 |
| Revenue This Year | $23.00 | $9.36 |
| Revenue Next Year | $19.69 | $15.43 |
| P/E Ratio | $514.50 | ★ N/A |
| Revenue Growth | ★ 29.57 | 4.29 |
| 52 Week Low | $23.38 | $22.28 |
| 52 Week High | $47.47 | $176.66 |
Technical Indicators
Market Signals| Indicator | IOT | MRNA |
|---|---|---|
| Relative Strength Index (RSI) | 59.82 | 63.18 |
| Support Level | $28.31 | $41.01 |
| Resistance Level | $42.00 | $176.66 |
| Average True Range (ATR) | 1.83 | 14.20 |
| MACD | 0.04 | 4.19 |
| Stochastic Oscillator | 77.19 | 65.65 |
Price Performance
Historical ComparisonAbout IOT Samsara Inc.
Samsara Inc provides an end-to-end solution for operations. The company's Connected Operations Platform consolidates data from its IoT devices and a growing ecosystem of connected assets and third-party systems, and makes it easy for organizations to access, analyze, and act on data insights using its cloud dashboard, custom alerts and reports, mobile apps, and workflows. The company derives almost all of its revenue from subscription services. Geographically, it derives a majority of its revenue from the United States. The company's customers range from small and medium-sized businesses to state and local governments.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.